ArticleTranslational cancer research2020
Clinicopathological characteristics and treatment outcomes of 162 Chinese patients with metastatic bladder cancer: results from a tertiary teaching hospital.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Site-specific heterogeneity in treatment response among patients with metastatic bladder cancer: implications for oligometastatic disease-a retrospective cohort study.Translational andrology and urology · 2026Article
- Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization.Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the relationship between clinicopathological features and prognosis of metastatic bladder cancer (MBC) patients in the real world, and to provide peculiar data support for the management of such patients.
methodsA retrospective analysis of 162 MBC patients who underwent radical cystectomy (RC) in West China Hospital, Sichuan University from September 2010 to December 2015 was conducted. The study included the clinical, pathological and metastatic features of these patients. Chi-square test, Kaplan-Meier method and Cox proportional hazard model were used to assess the relationship between clinicopathological factors and outcomes.
resultsOf the 162 patients enrolled, 137 (84.6%) were male and 25 (15.4%) were female. The ages at which the tumors metastasize for men and women were 64.8±9.4 and 66.2±12.7 years, respectively (P=0.52). The median follow-up time was 13.6 months (IQR: 5.8-33.1 months). Smoking history, pathological stages, and marginal status were independent predictors of the metastasis-free interval (MFI); Pathological stages, local recurrence, liver metastasis, and surgical approaches were significantly associated with cancer-specific survival (CSS) and overall survival (OS). Besides, OS was associated with lymphovascular invasion (LVI) and age at metastasis.
conclusionsOur study suggests that tumors in MBC patients with a smoking history, positive margins, pT3 or more advanced tumors are more likely to metastasize. Besides, patients with a minimally invasive surgery, local recurrence, and liver metastases are at greater risk of death from bladder cancer; Taken together, our study provides data support for an optimal management of patients with MBC in current real-world practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.